Lexaria Bioscience Corp. Files 8-K on Shareholder Vote Matters

Ticker: LEXX · Form: 8-K · Filed: Apr 24, 2024

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: LXRP

TL;DR

Lexaria (LXRP) is having a shareholder vote on key matters.

AI Summary

Lexaria Bioscience Corp. filed an 8-K on April 24, 2024, reporting on a submission of matters to a vote of security holders. The filing details information related to common stock and warrants, with the report date being April 23, 2024. The company is incorporated in Nevada and its principal executive offices are located in Kelowna, BC, Canada.

Why It Matters

This filing indicates that Lexaria Bioscience Corp. is engaging in a process that requires a vote from its security holders, which could impact the company's future direction or corporate structure.

Risk Assessment

Risk Level: medium — Filings related to shareholder votes can sometimes precede significant corporate actions or changes that may affect stock price.

Key Players & Entities

FAQ

What specific matters are being submitted for a vote of security holders?

The filing states it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific matters within the provided text.

When was the earliest event reported in this filing?

The earliest event reported was on April 23, 2024.

What is Lexaria Bioscience Corp.'s state of incorporation?

Lexaria Bioscience Corp. is incorporated in Nevada.

Where are Lexaria Bioscience Corp.'s principal executive offices located?

The principal executive offices are located at 100 – 740 McCurdy Road, Kelowna, BC Canada.

What is the SEC file number for Lexaria Bioscience Corp.?

The SEC file number is 001-39874.

Filing Stats: 607 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-04-24 11:38:28

Key Financial Figures

Filing Documents

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders On April 23, 2024 at 1:00 p.m. (Pacific Time), the Company held its annual shareholder meeting (the "Meeting"). There were 6,665,227 shares of the Company represented in person or by proxy at the Meeting, constituting 53.85% of the Company's issued share capital as at February 26, 2024, being the record date of the Meeting. The matters voted upon at the Meeting and the final voting results are set forth below: Matter Being Voted On For Against/ Withheld Abstain Broker Non-Vote Percent Approved By 1 To Elect Chris Bunka as a director 4,188,641 43,840 N/A 2,432,746 99 % To Elect John Docherty as a director 4,189,577 42,904 N/A 2,432,746 99 % To Elect Nicholas Baxter as a director 4,161,194 71,287 N/A 2,432,746 98 % To Elect Ted McKechnie as a director 3,735,858 496,623 N/A 2,432,746 88 % To Elect Albert Reese Jr. as a director 3,603,029 629,452 N/A 2,432,746 85 % To Elect Dr. Catherine Turkel as a director 4,181,783 50,698 N/A 2,432,746 99 % To Appoint Malone Bailey LLP as Auditors 6,566,179 59,519 39,529 0 99 % To Ratify the lawful actions of the directors for the past year 4,110,965 67,011 54,505 2,432,746 97 % 1 Percentage is calculated based on abstained votes being counted as a vote against the resolution. All of the proposals are described in detail in the Company's proxy statement filed with the Securities and Exchange Commission on March 6, 2024. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ Chris Bunka Chris Bunka CEO, Principal Executive Officer Date: April 24, 2024 3

View on Read The Filing